We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Submits NDA for Blood Disorder Treatment
GSK Submits NDA for Blood Disorder Treatment
December 21, 2007
GlaxoSmithKline (GSK) has filed a new drug application (NDA) to the FDA for approval to market Promacta for treating a rare blood disorder.